Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Scientists found a compound that appears to counter common mutations behind POLG-related diseases, rare conditions that harm ...

Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited tumor-infiltrating lymphocytes (TILs) may be ...

The International Space Station (ISS) executed evasive maneuvers Wednesday evening (April 30) to avoid a piece of passing ...

Olalekan O Oluwole, MD, MBBS, discussed a study on cytokine release syndrome and neurological events post axicabtagene ...

Brenan Cullimore had a rare genetic condition, Brugada syndrome, that led to cardiac arrest. His wife wants to raise ...

Genocury Biotech today revealed groundbreaking clinical data from its noval in vivo CD19 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), a notoriously aggressive blood ...

A large cohort study from China and the U.S. shows that Circadian Syndrome (CircS)—a cluster of metabolic and behavioral ...

Although the definition of acute respiratory distress syndrome (ARDS) has undergone numerous revisions aimed at enhancing its ...

Approval of Lynozyfic is based on data showing deep and durable responses in relapsed/refractory multiple myeloma Lynozyfic will provide a new option with convenient dosing and administration to patie ...

(NASDAQ: REGN) today announced that the European Commission (EC) has granted conditional marketing approval of Lynozyfic™ (linvoseltamab) to treat adults with relapsed and refractory (R/R) multiple ...

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing ...